- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Classen Immunotherapies, Inc. v. Elan Pharms., Inc.
Reanalyzing clinical data to identify patentable information and filing patent applications as well as making and selling a drug with a revised label reflecting the information derived from that clinical study falls into the ยง 271(e)(1) safe harbor provision and does not infringe as a matter of law.
October 25, 2016
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: Classen Immunotherapies, Inc. v. Elan Pharms., Inc., Case No. RDB-04-3521, 2016 U.S. Dist. LEXIS 131964 (D. Md. Sept. 27, 2016)
Drug Product and Patent(s)-in-Suit: Skelaxin® (metaxalone); U.S. Patent No. 6, 584,472 (“the ’472 patent”)
Nature of the Case and Issue(s) Presented: The district court received the case on remand from the Federal Circuit. The Federal Circuit had agreed with the district court’s conclusion of non-infringement because Elan’s activities were encompassed by the safe-harbor provision of § 271(e)(1) as relating to developing clinical data and submitting those data in an sNDA to the FDA. Because the district court did not consider activities—“(1) reanalyzing the clinical data to identify patentable information and filing patent applications; and (2) making and selling Skelaxin with the revised label that contained the information derived from the clinical study”—that occurred after the submission to the FDA, however, the Federal Circuit remanded the case for further proceedings. The court granted Elan’s motion for summary judgment of non-infringement.
Why Elan Prevailed: The court determined that both post-FDA submission activities fell within the scope of the § 271(e) safe harbor. In remanding the case, the Federal Circuit advised that, generally, filing a patent application is not infringement of a patent, nor is it an act of infringement when placing information submitted to the FDA on a product label after submitting an sNDA. Classen failed to provide any evidence that those general principles were inapplicable in this case. Elan’s post-FDA submission acts were not of a sufficiently commercial nature to form a basis for infringement. Thus, as a matter of law, Elan did not infringe Classen’s patent.
In addition, Classen provided no evidence that the reanalysis was for commercial purposes. Accordingly, even if the Elan could infringe as a matter of law, Classen failed to demonstrate that there was a genuine issue of material fact relating to infringement.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.